Rebeca Isais-Millán

Learn More
BACKGROUND Histamine has a selective affinity for H3 receptors and it may specifically inhibit the neurogenic edema response involved in migraine pathophysiology. OBJECTIVE To evaluate the therapeutic potential of subcutaneous administration of histamine in migraine prophylaxis, compared with oral administration of topiramate. METHODS Ninety patients(More)
BACKGROUND The histamine catabolite, Nalpha-methylhistamine, possesses a selective affinity for H3 receptors. For this reason, we considered evaluating the efficacy of this histaminergic H3 agonist in migraine prophylactic treatment. OBJECTIVE To study the therapeutic potential of the subcutaneous administration of Nalpha-methylhistamine in migraine(More)
Histamine has a selective affinity for H3-receptors and it may specifically inhibit the neurogenic edema response involved in migraine pathophysiology. The objective of this study was to evaluate the therapeutic potential of subcutaneous administration of histamine in migraine prophylaxis, compared with oral administration of sodium valproate, in an open(More)
OBJECTIVE Our aim was determine prevalence of intrafamily violence of the type physical-abuse, toward female claimants aged 18 years and older at the HGZ MF No. 1 in Colima. MATERIAL AND METHOD A transversal study was conducted in 288 females aged 18 years and older who were seen at the Family Medicine Unit for external consultation. RESULTS Average age(More)
BACKGROUND Subcutaneous histamine at low concentrations interacts with H3-receptors and may constitute a new therapeutic drug in migraine prophylaxis. It acts by limiting the excessive inflammatory response involved in migraine pathophysiology. OBJECTIVE Describe the results of a 15-year trial administering histamine at low concentrations. METHODS(More)
OBJECTIVES To compare the efficacy and tolerability of the subcutaneous administration of N alpha methyl histamine versus oral propranolol in the treatment of migraine prophylaxis. BACKGROUND N alpha methyl histamine has a selective affinity for H3 receptors and could constitute a new therapeutic drug in migraine prophylaxis. METHODS Sixty patients with(More)
  • 1